013nok
4,5 %
Date:2024-05-16Time:17:30:00Latest report:Q4-2022List:Oslo BorsTicker:BGBIO
Market Cap:510 mnokEnterprise Value:354 mnokNet Sales:0,35 mnokEarnings:-190,4 mnokEmployees:0ISIN:NO0010650013

Ratios

10-year key figure history for BerGenBio turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for BerGenBio with index and moving average MA50 and MA200.

Stockprice:0,13
MA50:0,16
MA200:0,18
Price/MA200:-29,1 %
RSI (14):38,3
Price/MA50:-20,8 %

Description

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

Biotechnology